Dr. Seth Forman to Chair XBiotech’s Second Phase 2 Study of Bermekimab in Atopic Dermatitis
XBiotech Inc. (XBIT)
Last xbiotech inc. earnings: 8/9 03:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
xbiotech.com/about/investors.html
Company Research
Source: GlobeNewswire
AUSTIN, Texas, July 11, 2019 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ: XBIT) announces that Seth Forman, M.D., will Chair the Company’s upcoming randomized, double-blind, placebo controlled Phase 2 study in Atopic Dermatitis (AD). This second Phase 2 study of bermekimab to treat moderate to severe AD in adults will build on results of a recently completed randomized study that showed rapid improvement in inflammatory lesions and pruritus. Dr. Forman is Board Certified in Dermatology and Dermatopathology, and has written numerous peer-reviewed articles in dermatology, including inflammatory skin conditions such as atopic dermatitis. He is the principal author of two chapters in the leading reference textbook for dermatologic therapeutics, Comprehensive Dermatologic Drug Therapy. Dr. Forman commented, “We are just now beginning to appreciate the key role that IL-1 alpha (IL-1?) plays in inflammatory skin disease. XBiotech’s recent Phase 2 results using its IL-1? blocker, bermekimab
Show less
Read more
Impact Snapshot
Event Time:
XBIT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
XBIT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
XBIT alerts
High impacting XBiotech Inc. news events
Weekly update
A roundup of the hottest topics